J Bonneterre
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Bonneterre J, Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7.
Nov 1, 2003Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
Nov 1, 2003European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7
Thürlimann Beat, Robertson J F R, Nabholtz J M, Buzdar A, Bonneterre J, Arimidex Study Group
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Nabholtz J, Bonneterre J, Buzdar A, Robertson J, Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9.
Aug 1, 2003Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Aug 1, 2003European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9
Nabholtz J M, Bonneterre J, Buzdar A, Robertson J F R, Thürlimann Beat
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-58.
Nov 1, 2001Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
Nov 1, 2001Cancer 2001; 92:2247-58
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann Beat, Robertson J F, Nabholtz J M, Buzdar A, Investigators Committee Members
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J, Thürlimann B, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57.
Nov 15, 2000Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
Nov 15, 2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J F, Thürlimann Beat, von Euler M
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
Vergote I, Steinberg M, Webster A, Koralewski L, Mauriac L, Krzakowski M, Robertson J, Thürlimann B, Bonneterre J, von Euler M. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2000; 36 Suppl 4:S84-5.
Sep 1, 2000Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
Sep 1, 2000European journal of cancer (Oxford, England : 1990) 2000; 36 Suppl 4:S84-5
Vergote I, Steinberg M, Webster A, Koralewski L, Mauriac L, Krzakowski M, Robertson J, Thürlimann Beat, Bonneterre J, von Euler M
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group
Thürlimann B, Zurlo M, Lanzalone S, di Salle E, Murray R, Roché H, Bonneterre J, Serin D, Paridaens R, Piscitelli G. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. European journal of cancer (Oxford, England : 1990) 1997; 33:1767-73.
Oct 1, 1997Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group
Oct 1, 1997European journal of cancer (Oxford, England : 1990) 1997; 33:1767-73
Thürlimann Beat, Zurlo M G, Lanzalone S, di Salle E, Murray R, Roché H, Bonneterre J, Serin D, Paridaens R, Piscitelli G